Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer. Dr. Deeg is a medical and pharmaceutical leader with broad experience developing drugs and digital therapeutics at companies from biopharma startups to pharmaceutical giants like Eli Lilly & Co., where he spent more than a decade.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a pioneer in transforming small molecule drug discovery by using machine learning and metabolomics to harness the potential of natural products, today announced the appointment of Vanitha Sekar, Ph.D., R.Ph., to the newly created position of Chief Business Officer. Dr. Sekar will play a key role in Enveda’s ongoing growth and will be responsible for shaping the company’s business development strategy.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-generation small molecule drugs, today announced the appointment of Robert J. Buckley as its Chief People Officer. Mr. Buckley is spearheading the company’s recruitment and development efforts to enhance the employee experience and bring additional strength to Enveda’s already robust team.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry, today announced that it will open two new drug discovery and development facilities to support its ongoing efforts to advance novel small molecule drugs.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, announced today the appointment of a new Chief Platform Officer (CPO), August Allen. The newly created position is designed to further scale and maximize Enveda’s proprietary drug discovery platform, drawing on skills that August honed during his five-year tenure at Recursion Pharmaceuticals.
Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced two key hires to accelerate its translational drug development efforts. It follows the closing of an oversubscribed $51M Series A financing round in June. Narayanan (Hari) Hariharan, MSc, Ph.D., has joined as Senior Vice President of Discovery Biology and Translational Sciences, alongside Indranil Mukhopadhyay, Ph.D., who now serves as Director of Drug Discovery Biology.
Enveda Biosciences pulled in $51 million in the raise, the company announced Tuesday morning, with the goal of pushing some of its preclinical programs further along. Led by CEO Viswa Colluru, Enveda aims to research how machine learning can utilize natural biology to create new therapies for Wilson’s Disease, NASH and Parkinson’s disease, among others.
Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs along with existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion.
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen therapeutics, has appointed Sotirios Karathanasis, Ph.D. as the company’s new Chief Science Officer. Dr. Karathanasis will spearhead the company’s small molecule drug discovery portfolio and work closely with Enveda’s preclinical team to advance the company’s lead programs for NASH and Wilson's Disease, along with a number of undisclosed programs.